Cited by 5,261Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Open access

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group·1998·New England Journal of Medicine

DOI 10.1056/nejm199811053391902

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199811053391902

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded?: Findings in 356 222 Primary Screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
Stamler, J. (1986) · JAMA · doi:10.1001/jama.1986.03380200061022 · Cited by 1,318
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537

Show all 21 references

Research works printed but not linked: 4

Peto R, 1985, Circulation, 72, 451
Keech A, 1992, Postgrad Med J, 68, 870
1994, Lancet, 344, 1383
Keech A, 1998, Atherosclerosis, 136, S31

Sorted by citations

Items 601–700 of 1,037

Fibrates, dyslipoproteinaemia and cardiovascular disease
Watts, G. F., & Dimmitt, S. B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00011 · Cited by 146
Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel
Chodick, G., Shalev, V., Gerber, Y., Heymann, A. D., Silber, H., Simah, V., & Kokia, E. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.012 · Cited by 145
Continuous Positive Airway Pressure Reduces Postprandial Lipidemia in Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Crossover Trial
Phillips, C. L., Yee, B. J., Marshall, N. S., Liu, P. Y., Sullivan, D. R., & Grunstein, R. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201102-0316oc · Cited by 145
Statin Safety: Lessons from New Drug Applications for Marketed Statins
Jacobson, T. A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.009 · Cited by 144
Obesity and cardiovascular disease
Abate, N. I. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00067-2 · Cited by 144
Effect of Genetic Polymorphism of OATP-C (SLCO1B1) on Lipid-Lowering Response to HMG-CoA Reductase Inhibitors
Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y., & Miki, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.375 · Cited by 144
Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with Hypercholesterolemia
Borghi, C., Prandin, M. G., Costa, F. V., Bacchelli, S., Esposti, D. D., & Ambrosioni, E. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200004000-00006 · Cited by 144
Clinical efficacy and safety of statins in managing cardiovascular risk
Kapur, N. K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1653 · Cited by 143
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model
Ferrara, D. E., Liu, X., Espinola, R. G., Meroni, P. L., Abukhalaf, I. K., Harris, E. N., & Pierangeli, S. S. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11449 · Cited by 143
Practical Implementation of the Guidelines for Unstable Angina/Non–ST-Segment Elevation Myocardial Infarction in the Emergency Department
Gibler, W. B., Cannon, C. P., Blomkalns, A. L., Char, D. M., Drew, B. J., Hollander, J. E., Jaffe, A. S., Jesse, R. L., Newby, L. K., Ohman, E. M., et al. (2005) · Circulation · doi:10.1161/01.cir.0000165556.44271.be · Cited by 143
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups
Blasetto, J. W., Stein, E. A., Brown, W. V., Chitra, R., & Raza, A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00003-1 · Cited by 143
Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: A retrospective cohort study
Yang, Y., Thumula, V., Pace, P. F., Banahan, B. F., Wilkin, N. E., & Lobb, W. B. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.10.002 · Cited by 143
Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis
Wong, N. D., Zhao, Y., Quek, R. G. W., Blumenthal, R. S., Budoff, M. J., Cushman, M., Garg, P. K., Sandfort, V., Tsai, M. Y., & López, J. A. G. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.015 · Cited by 142
Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis
Hippisley‐Cox, J., & Coupland, C. A. C. (2005) · BMJ · doi:10.1136/bmj.330.7499.1059 · Cited by 142
Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins
Rauch, U., Osende, J., Chesebro, J. H., Fuster, V., Vorchheimer, D. A., Harris, K., Harris, P., Sandler, D. A., Fallon, J. T., Jayaraman, S., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00397-x · Cited by 142
Evolution of statin prescribing 1994–2001: a case of agism but not of sexism?
DeWilde, S., Carey, I. M., Bremner, S. A., Richards, N., Hilton, S. R., & Cook, D. G. (2003) · Heart · doi:10.1136/heart.89.4.417 · Cited by 142
Selecting indicators for the quality of diabetes care at the health systems level in OECD countries
Nicolucci, A., Greenfield, S., & Mattke, S. (2006) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzl023 · Cited by 142
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
Bohula, E. A., Marston, N., Bhatia, A. K., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Park, J., Kuder, J., Murphy, S. A., Walsh, E., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514428 · Cited by 141
Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians
Snow, V. T., Aronson, M. D., Hornbake, E. R., Mottur-Pilson, C., & Weiss, K. B. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00012 · Cited by 141
Statins as potential therapeutic agents in neuroinflammatory disorders
Stüve, O., Youssef, S., Steinman, L., & Zamvil, S. S. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000073942.19076.d1 · Cited by 141
Plasma Lipoprotein(a) Concentration Predicts Future Coronary and Cardiovascular Events in Patients With Stable Coronary Heart Disease
Nestel, P. J., Barnes, E. H., Tonkin, A. M., Simes, J. R., Fournier, M., White, H. D., Colquhoun, D. M., Blankenberg, S., & SULLIVAN, D. R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302479 · Cited by 140
Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy
Takano, M., Mizuno, K., Yokoyama, S., Seimiya, K., Ishibashi, F., Okamatsu, K., & Uemura, R. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00770-8 · Cited by 140
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease
Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., & for the Treating to New Targets Study Steering Committee and Investigators (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00002 · Cited by 139
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Exposure to statins and risk of common cancers: a series of nested case-control studies
Vinogradova, Y., Coupland, C. A. C., & Hippisley‐Cox, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-409 · Cited by 139
Long-term statin use and psychological well-being
Young‐Xu, Y., Chan, K. A., Liao, J. K., Ravid, S., & Blatt, C. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00785-x · Cited by 139
Fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
Ferrara, D. E., Swerlick, R. A., Casper, K., Meroni, P. L., Vega-Ostertag, M. E., Harris, E. N., & Pierangeli, S. S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00896.x · Cited by 139
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 139
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin
Downs, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01464-3 · Cited by 138
Cholesterol and cardiovascular disease in the elderly. Facts and gaps.
Félix-Redondo, F. J., Grau, M., & Fernandez-Berges, D. J. (2013) · Europe PMC (PubMed Central) · Cited by 138
Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery
Collard, C. D., Body, S. C., Shernan, S. K., Wang, S. V., & Mangano, D. T. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.04.009 · Cited by 138
Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury
Indolfi, C., Cioppa, A., Stabile, E., Lorenzo, E. D., Esposito, G., Pisani, A., Leccia, A., Cavuto, L., Stingone, A. M., Chieffo, A., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00526-4 · Cited by 138
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
Chapman, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.003 · Cited by 138
Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada
Miller, M. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.3.343 · Cited by 138
Untitled work
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Non-adherence to statin therapy: a major challenge for preventive cardiology
Bates, T., Connaughton, V., & Watts, G. F. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903376186 · Cited by 137
Statin Use and the Risk of Breast and Prostate Cancer
Coogan, P. F., Rosenberg, L. A., Palmer, J. R., Strom, B. L., Zauber, A. G., & Shapiro, S. (2002) · Epidemiology · doi:10.1097/00001648-200205000-00005 · Cited by 137
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136
Inclusion of Stroke in Cardiovascular Risk Prediction Instruments
Lackland, D. T., Elkind, M. S. V., D’Agostino, R. B., Dhamoon, M. S., Goff, D. C., Higashida, R. T., McClure, L. A., Mitchell, P. H., Sacco, R. L., Sila, C. A., et al. (2012) · Stroke · doi:10.1161/str.0b013e31825bcdac · Cited by 136
Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot
Lu, J., Xuan, S., Downing, N. S., Wu, C., Li, L., Krumholz, H. M., & Jiang, L. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010200 · Cited by 136
Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators
Brigadeau, F., Kouakam, C., Klug, D., Marquié, C., Duhamel, A., Mizon-Gérard, F., Lacroix, D., & Kacet, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi726 · Cited by 136
Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
Zhou, Y., Ye, X., Yu, F., Zhang, X., Qin, Y., Lu, J., & He, J. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-1 · Cited by 135
Thirty-year Trends in Cardiovascular Risk Factor Levels among US Adults with Diabetes: National Health and Nutrition Examination Surveys, 1971-2000
Imperatore, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh232 · Cited by 135
The Evidence For and Against Evidence-Based Practice
Mullen, E. J., & Streiner, D. L. (2004) · Brief Treatment and Crisis Intervention · doi:10.1093/brief-treatment/mhh009 · Cited by 134
Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 134
The National Cholesterol Education Program
Cleeman, J. I., & Lenfant, C. J. M. (1998) · JAMA · doi:10.1001/jama.280.24.2099 · Cited by 134
Oat-derived β-Glucan Significantly Improves HDLC and Diminishes LDLC and Non-HDL Cholesterol in Overweight Individuals With Mild Hypercholesterolemia
Reyna-Villasmil, N., Bermúdez, V., Mengual-Moreno, E., Arias, N., Cano-Ponce, C., Leal, E., Souki, A. J., Inglett, G. E., Israili, Z. H., Hernández-Hernández, R., et al. (2007) · American Journal of Therapeutics · doi:10.1097/01.pap.0000249917.96509.e7 · Cited by 133
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B
Chotiyaputta, W., Peterson, C., Ditah, F. A., Goodwin, D., & Lok, A. S.-F. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.016 · Cited by 133
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long‐term Intervention with Pravastatin in Ischaemic Disease (LIPID) study
Magliano, D. J., Liew, D., Pater, H., Kirby, A. C., Hunt, D. U., Simes, J. R., Sundararajan, V., & Tonkin, A. M. (2003) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2003.tb00615.x · Cited by 133
Diabetes and macrovascular disease
Vinik, A. I., & Flemmer, M. C. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00212-4 · Cited by 133
Large Scale Cohort Study of the Relationship Between Serum Cholesterol Concentration and Coronary Events With Low-Dose Simvastatin Therapy in Japanese Patients With Hypercholesterolemia and Coronary Heart Disease: Secondary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT)
Mabuchi, H., Kita, T., Matsuzaki, M., Matsuzawa, Y., Nakaya, N., Oikawa, S., Saito, Y., Sasaki, J., Shimamoto, K., Itakura, H., et al. (2002) · Circulation Journal · doi:10.1253/circj.66.1096 · Cited by 132
Self-citation
Evaluation of different formulas for LDL-C calculation
Vujović, A., Kotur‐Stevuljević, J., Spasić, S., Bujišić, N., Martinović, J., Vujović, M., Spasojević‐Kalimanovska, V., Zeljković, A., & Pajic, D. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-27 · Cited by 132
CKD and Sudden Cardiac Death
Whitman, I. R., Feldman, H. I., & Deo, R. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010037 · Cited by 132
Biologic Effects of Simvastatin in Patients with Aneurysmal Subarachnoid Hemorrhage: A Double-Blind, Placebo-Controlled Randomized Trial
Vergouwen, M. D. I., Meijers, J. C. M., Geskus, R. B., Coert, B. A., Horn, J., Stroes, E. S. G., van der Poll, T., Vermeulen, M., & Roos, Y. B. W. E. M. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.59 · Cited by 132
Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction
Schneeweiß, S., Patrick, A. R., Maclure, M., Dormuth, C. R., & Glynn, R. J. (2007) · Circulation · doi:10.1161/circulationaha.106.665992 · Cited by 132
Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease
Franceschini, G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02146-4 · Cited by 131
The effects of oral anti‐hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes
Buse, J. B., Tan, M. H., PRINCE, M. J., & Erickson, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00325.x · Cited by 131
The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys
van Heek, M., Compton, D. S., & Davis, H. R. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00825-1 · Cited by 131
New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy
Davison, S. L., & Davis, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021929 · Cited by 131
Statins and chronic heart failure: do we need a large-scale outcome trial?
Krum, H., & McMurray, J. J. V. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01827-2 · Cited by 131
Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
Horne, B. D., Muhlestein, J. B., Carlquist, J. F., Bair, T. L., Madsen, T. E., Hart, N. I., & Anderson, J. L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00950-5 · Cited by 131
Efficacy of n‐3 polyunsaturated fatty acids after myocardial infarction: Results of GISSI‐prevenzione trial
Marchioli, R., Schweiger, C., Tavazzi, L., & Valagussa, F. (2001) · Lipids · doi:10.1007/s11745-001-0694-8 · Cited by 131
Downregulation of Angiotensin II Type 1 Receptor by Hydrophobic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Vascular Smooth Muscle Cells
Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Egashira, K., Shimokawa, H., Hirano, K., Kanaide, H., & Takeshita, A. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1201.099430 · Cited by 130
Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease
Majumdar, S. R., Gurwitz, J. H., & Soumerai, S. B. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.02229.x · Cited by 130
Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome
Hirsh, B. J., Smilowitz, N. R., Rosenson, R. S., Fuster, V., & Sperling, L. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.030 · Cited by 129
Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)
Wilcox, R., Kupfer, S., & Erdmann, E. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.029 · Cited by 129
The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials
Saha, S. A., Kizhakepunnur, L. G., Bahekar, A., & Arora, R. R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.011 · Cited by 129
Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis
Ni, W., Egashira, K., Kataoka, C., Kitamoto, S., Koyanagi, M., Inoue, S., & Takeshita, A. (2001) · Circulation Research · doi:10.1161/hh1701.096614 · Cited by 129
Sympathetic Nerve Sprouting, Electrical Remodeling, and Increased Vulnerability to Ventricular Fibrillation in Hypercholesterolemic Rabbits
Liu, Y., Wu, C., Lu, L., Su, M., Lin, C., Lin, S., Chen, L. S., Fishbein, M. C., Chen, P., & Lee, Y. (2003) · Circulation Research · doi:10.1161/01.res.0000072999.51484.92 · Cited by 129
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,⁎Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease)
Hirsch, A. T., Haskal, Z. J., HERTZER, N. R., Bakal, C. W., Creager, M. A., Halperin, J. L., Hiratzka, L. F., Murphy, W. R. C., Olin, J. W., Puschett, J. B., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.024 · Cited by 129
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study
Paoletti, R., Fahmy, M. I., Mahla, G., Mizan, J., & Southworth, H. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800608 · Cited by 129
Stroke prevention, blood cholesterol, and statins
Amarenco, P., Lavallée, P. C., & Touboul, P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00734-3 · Cited by 129
The Effect of Aggressive Versus Standard Lipid Lowering by Atorvastatin on Diabetic Dyslipidemia
The Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1335 · Cited by 128
Self-citation
Approach to lipoprotein management in 2001 National Cholesterol Guidelines
Grundy, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02631-0 · Cited by 128
Long-term risk stratification for survivors of acute coronary syndromes
Marschner, I. C., Colquhoun, D. M., Simes, R. J., Glasziou, P., Harris, P., Singh, B., Friedlander, D. H., White, H. D., Thompson, P., & Tonkin, A. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01360-2 · Cited by 128
Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists
Libby, P., & Plutzky, J. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.004 · Cited by 128
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis
Bhatia, H. S., Wandel, S., Willeit, P., Lesogor, A., Bailey, K., Ridker, P. M., Nestel, P. J., Simes, R. J., Tonkin, A. M., Schwartz, G. G., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069556 · Cited by 127
Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario
Mohan, V., Venkatraman, J. V., & Pradeepa, R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400121 · Cited by 127
Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients
Maycock, C. A. A., Muhlestein, J. B., Horne, B. D., Carlquist, J. F., Bair, T. L., Pearson, R. R., Li, Q., & Anderson, J. L. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02477-4 · Cited by 127
Joint British recommendations on prevention of coronary heart disease in clinical practice
Cheesman, M., Leech, G. J., Chambers, J. B., Monaghan, M. J., & Nihoyannopoulos, P. (1998) · Heart · doi:10.1136/hrt.80.2008.1s · Cited by 176
Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients
Sukhija, R., Prayaga, S., Marashdeh, M., Bursac, Z., Kakar, P., Bansal, D., Sachdeva, R., Kesan, S. H., & Mehta, J. L. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318197ec8b · Cited by 126
Number of Yellow Plaques Detected in a Coronary Artery Is Associated With Future Risk of Acute Coronary Syndrome
Ohtani, T., Ueda, Y., Mizote, I., Oyabu, J., Okada, K., Hirayama, A., & Kodama, K. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.01.064 · Cited by 126
Using Pravastatin to Improve the Vascular Reactivity in a Mouse Model of Soluble Fms-Like Tyrosine Kinase-1–Induced Preeclampsia
Costantine, M. M., Tamayo, E. H., Lu, F., Bytautiene, E., Longo, M., Hankins, G. D. V., & Saade, G. R. (2010) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3181e10ebd · Cited by 126
Oxidative stress and endothelial dysfunction: Therapeutic implications
Gori, T., & Münzel, T. F. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.543920 · Cited by 126
How Well Are Hypertension, Hyperlipidemia, Diabetes, and Smoking Managed After a Stroke or Transient Ischemic Attack?
Mouradian, M. S., Majumdar, S. R., Senthilselvan, A., Khan, K. A., & Shuaib, A. M. (2002) · Stroke · doi:10.1161/01.str.0000017877.62543.14 · Cited by 126
Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial
Liem, A. H. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3291 · Cited by 126
Fluvastatin Prevents Cardiac Death and Myocardial Infarction in Renal Transplant Recipients: Post-Hoc Subgroup Analyses of the ALERT Study
Jardine, A. G., Holdaas, H., Fellström, B., Cole, E., Nyberg, G., Grönhagen‐Riska, C., Madsen, S., Neumayer, H., Maes, B., Ambühl, P. M., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00445.x · Cited by 125
Use of statins in CNS disorders
Cucchiara, B. L., & Kasner, S. E. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00529-9 · Cited by 125
Early Withdrawal of Statin Therapy in Patients With Non–ST-Segment Elevation Myocardial Infarction National Registry of Myocardial Infarction
Spencer, F. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2162 · Cited by 125
Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer
Eliassen, A. H., Colditz, G. A., ROSNER, B. A., Willett, W. C., & Hankinson, S. E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.19.2264 · Cited by 124
Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease
Bickel, C., Rupprecht, H. J., Blankenberg, S., Espinola–Klein, C., Schlitt, A., Rippin, G., Hafner, G., Treude, R., Othman, H., Hofmann, K.-P., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02236-1 · Cited by 123
Toward Immunomodulatory and Anti-Inflammatory Properties of Statins
Arnaud, C., Braunersreuther, V., & Mach, F. (2005) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2005.07.002 · Cited by 123
Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry
Hanania, G., Cambou, J.-P., Guéret, P., Vaur, L., Blanchard, D., Lablanche, J.-M., Boutalbi, Y., Humbert, R., Clerson, P., Genès, N., et al. (2004) · Heart · doi:10.1136/hrt.2003.025460 · Cited by 123
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)—TIMI 22 trial
Cannon, C. P., McCabe, C. H., Belder, R., Breen, J. D., & Braunwald, E. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02201-4 · Cited by 122
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Auer, J., Weber, T., & Eber, B. (2004) · New England Journal of Medicine · doi:10.1056/nejm200408123510719 · Cited by 122
The role of statins in the prevention of preeclampsia
Smith, D. D., & Costantine, M. M. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.08.040 · Cited by 121
Monitoring Cholesterol Levels: Measurement Error or True Change?
Glasziou, P., Irwig, L., Heritier, S. R., Simes, R. J., Tonkin, A. M., & for the LIPID Study Investigators (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00005 · Cited by 121
Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Mannu, G., Zaman, M., Gupta, A., Rehman, H. U., & Myint, P. K. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076313 · Cited by 121
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Packard, C. J., Ford, I., Robertson, M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Gaw, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.526848 · Cited by 121

Authors: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Affiliations: The University of Sydney (AU)
Corresponding author: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-11-05
Volume: 339
Issue: 19
Pages: 1349-1357
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199811053391902
OpenAlex: W38523360
Cited by: 5,261
References: 21
Citations by year: 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
FWCI: 312.19
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
MeSH terms: Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks